Arca
Skip to content
Tools
Tools

ERBB3: Receptor tyrosine-protein kinase erbB-3

Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation.

  • Drugs that act on it: 11
  • Approved: 0
  • In phases 1 to 3: 11
  • Sponsors: 8

Who is on it, and how far along

Every drug ChEMBL records acting on ERBB3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 6
  • Antibody-drug conjugate 1
  • Other 3

Approved0

    Phase 32

    • Patritumab
    • Patritumab deruxtecan

    Phase 28

    • Sapitinib
    • AMG-888
    • CDX-3379
    • Duligotuzumab
    • Elgemtumab
    • Istiratumab
    • Lumretuzumab
    • Seribantumab

    Phase 11

    • AV-203

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 11 act as: Receptor tyrosine-protein kinase erbB-3 inhibitor; the rest name their own mechanism.
    PatritumabPhase 3Merck & Co. (MSD)AntibodyInhibitor22
    Patritumab deruxtecanPhase 3Merck & Co. (MSD)Antibody-drug conjugateBinding agentReceptor tyrosine-protein kinase erbB-3 binding agent22
    SapitinibPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor1
    AMG-888Phase 2U3 Pharma GmbHOtherInhibitor0
    CDX-3379Phase 2Celldex TherapeuticsOtherInhibitor0
    DuligotuzumabPhase 2RocheAntibodyInhibitor0
    ElgemtumabPhase 2Novartis PharmaceuticalsAntibodyInhibitor0
    IstiratumabPhase 2Merrimack PharmaceuticalsAntibodyInhibitor0
    LumretuzumabPhase 2RocheAntibodyInhibitor0
    SeribantumabPhase 2Merrimack PharmaceuticalsAntibodyAntagonistReceptor tyrosine-protein kinase erbB-3 antagonist0
    AV-203Phase 1LG ChemOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
    A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerPatritumab, Patritumab deruxtecanPhase 1 / Phase 2RecruitingDaiichi SankyoJul 14, 2026
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Patritumab, Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCDec 16, 2025
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Patritumab, Patritumab deruxtecanPhase 3RecruitingMerck Sharp & Dohme LLCJul 11, 2025
    A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Patritumab, Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCApr 23, 2025
    Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)Patritumab, Patritumab deruxtecanPhase 2RecruitingMerck Sharp & Dohme LLCJan 28, 2025
    A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)Patritumab, Patritumab deruxtecanPhase 2RecruitingMerck Sharp & Dohme LLCDec 13, 2024
    Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)Patritumab, Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCNov 13, 2024
    Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Patritumab, Patritumab deruxtecanPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCSep 19, 2024
    SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerSapitinibPhase 2Active, not recruitingUNICANCERNov 24, 2014

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Visceral neuropathy, familial, 1, autosomal recessive0.73
    • Lethal congenital contracture syndrome 20.70
    • Cancer0.66
    • Urinary bladder carcinoma0.60
    • Non-small cell lung carcinoma0.59
    • Neoplasm0.56
    • Medullary thyroid gland carcinoma0.54
    • Colorectal adenocarcinoma0.53
    • Type 1 diabetes mellitus0.46
    • Erythroleukemia, familial, susceptibility to0.45
    • Gastric adenocarcinoma0.45

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5838, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21860, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.